AmpliPhi Bio To Hold Business Update Conference Call On May 15

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:			U.S.	877-866-5534
			International	346-406-0930
			Passcode	20313217
Live Webcast:			AmpliPhi IR Website
			The webcast replay will be available approximately 2 hours
			after completion of the call and will be archived for 30 days.
Replay:			U.S.	855-859-2056
			International	404-537-3406
			Passcode	20313217
			The replay will be available for 48 hours starting approximately
			2 hours after completion of the call.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.